# A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

> **NCT03463369** · PHASE1 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 30 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **BIOLOGICAL:** JNJ-64300535
- **BIOLOGICAL:** Placebo
- **DRUG:** Nucleos(t)ide Analogs (NA)

## Key facts

- **NCT ID:** NCT03463369
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-18
- **Primary completion:** 2021-03-23
- **Final completion:** 2021-03-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463369, "A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03463369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*